Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Harmony Biosciences Holdings (HRMY)

Harmony Biosciences names COO Peter Anastasiou CEO effective Jan. 1, 2027

Neutral Impact 4 of 5 leadership Written later

Harmony Biosciences said CEO Jeffrey M. Dayno, M.D., will retire and leave the board on December 31, 2026, as part of a planned succession. Chief Operating Officer Peter Anastasiou will become President, Chief Executive Officer and a Class I director on January 1, 2027, and the company reiterated its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.

Key points

  • Dayno retires as President and CEO and steps down from the board on December 31, 2026, and will serve as a non-executive advisor through 2027.
  • Anastasiou, COO since April 2026, becomes President and CEO effective January 1, 2027, and joins the board as a Class I director.
  • The company reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
  • Harmony still expects to report multiple ascending dose study data for BP-205 in Q4 2026.

The filing

CompanyHarmony Biosciences Holdings (HRMY)
Form8-K, current report
Filed with the SECOct 13, 2026, 8:00 AM ET
Accession number0001104659-26-115282

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.